An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,503

Participants

Timeline

Start Date

November 19, 2015

Primary Completion Date

June 30, 2026

Study Completion Date

December 29, 2028

Conditions
Prostatic Neoplasms
Interventions
DRUG

Apalutamide

DRUG

Bicalutamide

DRUG

Bicalutamide Placebo

DRUG

Apalutamide Placebo

DRUG

GnRH (agonist)

RADIATION

74-80 Grays (units of radiation)

Trial Locations (262)

Unknown

Homewood

Chandler

Scottsdale

Tucson

Bakersfield

Los Angeles

Orange

San Bernardino

San Diego

San Francisco

Aurora

Denver

Middlebury

Bradenton

Daytona Beach

Fort Myers

Hialeah

Lakewood Rch

Naples

Plantation

Meridian

Evergreen Park

Harvey

Jeffersonville

Wichita

Ashland

New Orleans

Shreveport

Scarborough

Baltimore

Boston

St Louis

Morristown

Albany

Brooklyn

New York

Poughkeepsie

Rochester

Syracuse

The Bronx

Cary

Raleigh

Portland

Springfield

Bala-Cynwyd

Bryn Mawr

Lancaster

Philadelphia

East Greenwich

Charleston

Myrtle Beach

Nashville

Dallas

Houston

San Antonio

Fairfax

Virginia Beach

Burien

Spokane

Morgantown

Buenos Aires

C.a.b.a.

Caba

Pergamino

Rosario

San Salvador de Jujuy

Aalst

Antwerp

Bonheiden

Brussels

Haine-St-Paul

Leuven

Liège

Namur

Roeselare

Sint-Niklaas

Turnhout

Barretos

Belo Horizonte

Campinas

Curitiba

Florianópolis

Goiânia

Ijuí

Natal

Porto Alegre

Ribeirão Preto

Rio de Janeiro

Salvador

Santo André

São José do Rio Preto

São Paulo

Sorocaba

Calgary

Surrey

Vancouver

Victoria

London

Ottawa

Toronto

Gatineau

Laval

Montreal

Québec

Sherbrooke

Beijing

Chengdu

Chongqing

Guangzhou

Hangzhou

Nanchang

Nanjing

Ningbo

Shanghai

Wuhan

Xi'an

Hradec Králove

Liberec

Nový Jicin

Olomouc

Opava

Pardubice

Prague

Zlín

Amiens

Angers

Avignon

Bayonne

Besançon

Bordeaux

Brest

Dijon

Évry-Courcouronnes

Hyères

La Tronche

Le Mans

Lille

Marseille

Marseilli

Montpellier

Neuilly-sur-Seine

Paris

Ris-Orangis

Saint-Brieuc

Saint-Herblain

Saint-Mandé

Saint-Priest-en-Jarez

Strasbourg

Toulouse

Tours

Vandœuvre-lès-Nancy

Villejuif

Braunschweig

Chemnitz

Dessau

Frankfurt

Gronau

Jena

Münster

Nürtingen

Ulm

Weiden

Beer Yaakov

Beersheba

Haifa

Jerusalem

Kfar Saba

Petah Tikva

Ramat Gan

Tel Aviv

George Town

Kuala Lumpur

Kuching

Putrajaya

Culiacán

Guadalajara

León

México

Morelia

Zapopan

Alkmaar

Amsterdam

Nijmegen

Rotterdam

The Hague

Bialystok

Bydgoszcz

Gdynia

Gliwice

Kielce

Lodz

Olsztyn

Poznan

Wałbrzych

Bucharest

Cluj-Napoca

Floreşti

Iași

Otopeni

Ploieşti

Sibiu

Târgu Mureş

Timișoara

Barnaul

Ivanovo

Moscow

Nizhny Novgorod

Obninsk

Omsk

Pyatigorsk

Rostov-on-Don

Ryazan

Saint Petersburg

Saransk

Tambov

Tyumen

Ufa

Vologda

Daegu

Gyeonggi-do

Jeollanam-do

Seoul

Barakaldo

Barcelona

Castellon

L'Hospitalet de Llobregat

Las Palmas de Gran Canaria

Madrid

Málaga

Reus

Santiago de Compostela

Seville

Örebro

Stockholm

Umeå

Kaohsiung City

Taichung

Tainan City

Taipei

Taoyuan District

Adana

Ankara

Edirne

Istanbul

Izmir

Kayseri

Kocaeli

Dnipro

Khakhiv

Kyiv

Lviv

Aberdeen

Birmingham

Bristol

Derby

Glasgow

Oxford

Plymouth

Preston

Sheffield

Sutton

Wolverhampton

Sponsors
All Listed Sponsors
lead

Aragon Pharmaceuticals, Inc.

INDUSTRY